68-04-2Relevant academic research and scientific papers
COMPOSITION AND METHOD FOR THE TREATMENT OF COVID-19
-
Paragraph 0038, (2021/11/13)
A composition and method for treating COVID 19 by orally administering a pharmacological composition comprising a pharmaceutical carrier and an active composition consisting of about 82% to about 92% Sodium citrate, about 8% to about 18% citric acid and an effective amount of zinc sulfate.
CROSS-LINKED COMPOSITIONS
-
, (2011/05/16)
Improved compositions comprising a cross-linkable protein or polypeptide, and a non-toxic material which induces cross-linking of the cross-linkable protein. The compositions are optionally and preferably prepared in a non-phosphate buffer solvent. Optionally and preferably, the cross-linkable protein includes gelatin and any gelatin variant or variant protein as described herein. Optionally and preferably, the non-toxic material comprises transglutaminase (TG), which may optionally comprise any type of calcium dependent or independent transglutaminase, which may for example optionally be a microbial transglutaminase (mTG).
CO-PRECIPITATED SALTS OF FATTY ACIDS
-
, (2011/10/12)
A co-salt of a polyunsaturated fatty acid and a non-fatty acid is formed as a precipitate. The co-salt formed is free flowing and does not tend to agglomerate (cake) in storage. The resultant co-salt product will be easy to blend with other products to produce dietary supplements. These novel co-salt products may also tablet very well and may be added to current dietary supplement tablets.
DIALYSIS SOLUTIONS CONTAINING PYROPHOSPHATES
-
, (2009/04/24)
Dialysis solutions comprising pyrophosphates and methods of making and using the dialysis solutions are provided. In an embodiment, the present disclosure provides a dialysis solution comprising a stable and therapeutically effective amount of pyrophosphate. The dialysis solution can be sterilized, for example, using a technique such as autoclave, steam, high pressure, ultra-violet, filtration or combination thereof. The dialysis solution can be in the form of a concentrate.
Effervescent composition and tablet made there from
-
, (2008/06/13)
The present invention relates to an acidic effervescent component for direct tableting of effervescent tablets and a process for its preparation.
Injectable mesna solutions
-
, (2008/06/13)
Injectable mesna solutions having a pH value higher than 7.5. The solutions have increased storage stability.
Enteric coating liquid
-
, (2008/06/13)
An aqueous enteric coating liquid having a good dispersion stability and a good resistance to gastric juice comprising an alkali metal salt of an acid having a acid dissociation constant of at least 3 at 25° C. and a water-insoluble oxycarboxylic acid type cellulose derivative dispersed in water or a mixture of water and at most 20% by weight of a lower alcohol.
New pharmaceutical forms for administration of medicaments by oral route, with programmed release
-
, (2008/06/13)
The present invention relates to a new pharmaceutical form for oral use in the nature of delayed action and controlled absorption medicaments. This form comprises an association of miniaturized granules obtained by high to very high compression: (a) with pH control agents, (b) coated with excipients determining the slow penetration of digestive and/or (c) coated with a very thin layer of lipids. These miniaturized granules may contain glucose, nay have pH control agents with different solubilities, and may be in the form of miniaturized granules with a pH gradient.
Norbornyl pyridine derivatives, organoleptic uses of same, and the processes for preparing same
-
, (2008/06/13)
Described are norbornyl pyridine derivatives defined according to the generic structure: STR1 wherein R5, R5 ', R5 ", R5 '" and R5 "" each represents hydrogen or methyl with the proviso that at least four of R5, R5 ', R5 ", R5 '" and R5 "" represent hydrogen; wherein the dashed line represents a carbon-carbon single bond or a carbon-carbon double bond and wherein the pyridinyl moiety is bonded to the norbornyl moiety at the 2' position of the norbornyl moiety and at either the 2 or the 4 position of the pyridinyl moiety as well as organoleptic uses thereof in augmenting or enhancing the aroma or taste of foodstuffs, chewing gums, toothpastes, chewing tobaccos, medicinal products, perfume compositions, colognes and perfumed articles including, but not limited to solid or liquid anionic, cationic, zwitterionic and nonionic detergents, cosmetic compositions, fabric softener compositions, fabric softener articles, hair preparations, and perfumed polymers. Also described are processes for preparing such compounds comprising reacting vinyl pyridines defined according to the structure: STR2 wherein one of R1 or R2 is hydrogen and the other of R1 or R2 is vinyl with a bicyclopentadiene derivative defined according to the structure: STR3 wherein R3, R3 ', R3 ", R3 '" and R3 "" each represents hydrogen or methyl with the proviso that at least four of R3, R3 ', R3 ", R3 '" and R3 "" represent hydrogen and wherein R4, R4 ', R4 ", R4 '" and R4 "" each represents hydrogen or methyl with at least four of R4, R4 ', R4 ", R4 '" and R4 "" representing hydrogen and then as desired hydrogenating the resulting product.
Organic complex of platinum, its preparation and its use for treating malignant tumors
-
, (2008/06/13)
An organic complex of platinum, cis-isocitrato (1,2 diaminocyclohexane) platinum (II) having improved anti-tumor activity and water-solubility. The complex is prepared by reacting cis-dichloro (1,2-diaminocyclohexane) platinum (II) with silver nitrate, removing the silver chloride formed, and reacting the resulting liquid with trisodium isocitrate. The complex is administered in the form of a pharmaceutical composition.
